Investment House LLC maintained its stake in Abiomed Inc. (NASDAQ:ABMD) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 4,000 shares of the company’s stock at the end of the second quarter. Investment House LLC’s holdings in Abiomed were worth $437,000 as of its most recent filing with the SEC.
Several other large investors have also bought and sold shares of ABMD. Bank of Montreal Can acquired a new stake in Abiomed during the second quarter worth approximately $8,459,000. Oakbrook Investments LLC bought a new position in shares of Abiomed during the second quarter worth $423,000. YHB Investment Advisors Inc. raised its position in shares of Abiomed by 9.1% in the second quarter. YHB Investment Advisors Inc. now owns 9,167 shares of the company’s stock worth $1,002,000 after buying an additional 767 shares in the last quarter. LS Investment Advisors LLC raised its position in shares of Abiomed by 68.4% in the second quarter. LS Investment Advisors LLC now owns 2,615 shares of the company’s stock worth $286,000 after buying an additional 1,062 shares in the last quarter. Finally, IBM Retirement Fund bought a new position in shares of Abiomed during the second quarter worth $438,000. Hedge funds and other institutional investors own 93.65% of the company’s stock.
Abiomed Inc. (NASDAQ:ABMD) traded down 0.42% on Thursday, reaching $126.37. 334,204 shares of the company’s stock were exchanged. The company has a market cap of $5.41 billion, a P/E ratio of 134.44 and a beta of 0.89. Abiomed Inc. has a 12-month low of $67.81 and a 12-month high of $127.86. The firm has a 50 day moving average of $121.00 and a 200-day moving average of $106.20.
Abiomed (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.06. Abiomed had a net margin of 11.75% and a return on equity of 11.86%. The business had revenue of $103 million for the quarter, compared to analyst estimates of $97.23 million. During the same period in the previous year, the business posted $0.20 earnings per share. The business’s revenue was up 40.3% compared to the same quarter last year. Equities analysts expect that Abiomed Inc. will post $1.17 EPS for the current fiscal year.
A number of brokerages recently weighed in on ABMD. Zacks Investment Research lowered shares of Abiomed from a “buy” rating to a “hold” rating in a research note on Friday, August 12th. Jefferies Group raised their price target on shares of Abiomed from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $115.59.
In other news, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 29th. The shares were sold at an average price of $106.58, for a total transaction of $1,065,800.00. Following the transaction, the vice president now directly owns 65,558 shares in the company, valued at $6,987,171.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael R. Minogue sold 58,710 shares of the business’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $127.00, for a total transaction of $7,456,170.00. Following the transaction, the chief executive officer now owns 215,782 shares in the company, valued at $27,404,314. The disclosure for this sale can be found here. Insiders own 10.00% of the company’s stock.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abiomed Inc. (NASDAQ:ABMD).
Receive News & Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.